Drug Trial Radar · NCT00549068
POWER Point of Care Effect on Satisfaction of Treatment
Last checked: Nov 20, 2026Latest source record: Dec 7, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,433
Actual
Start
Feb 2003
Primary completion
Not stated
Study completion Nov 2004
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Procter and Gamble
- First posted
- Oct 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption marker results using the NTx Point-Of-Care (POC) device, to similar women treated as per regular clinical practice
Conditions
- Osteoporosis, Postmenopausal
Interventions
Risedronate Sodium (Actonel)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel® 35 mg Once-a-Week for 24 weeks, and receiving feedback information after 12 weeks of treatment to similar women monitored as per regular clinical practice
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.